With respect to assay development, quality assurance and, ultimately, clinical adoption, the primary subject of this review, these advantages are critical. Implicit with these advantages, TMAs enable ...

Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...

Uterine fibroids are benign tumors that occur in a large proportion of women and interfere with the proper functioning of this organ. One of the factors leading to these proliferative changes appears ...

EYSINS, Switzerland, April 3, 2025 /PRNewswire/ --Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® ...

New AI-driven tool converts common histology images into detailed, multi-layered cancer markers, promising faster, more accurate diagnostics and improved patient outcomes. Study: Accelerating ...

Progression-free survival and platinum chemoresistance may be predicted by tumor-stroma proportion in patients with high-grade serous ovarian cancer. Tumor-stroma proportion (TSP) may predict clinical ...